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Both donors and acceptors of communication-mediating (COM) domains are
essential for coordinating intermolecular communication within nonribosomal peptides
synthetases (NRPSs) complexes. Different sets of COM domains provide selectivity,
allowing NRPSs to utilize different natural biosynthetic templates. In this study,
novel lipopeptides were synthesized by reprogramming the plipastatin biosynthetic
machinery. A Thr-to-Asp point mutation was sufficient to shift the selectivity of the
donor COM domain of ppsB toward that of ppsD. Deletion and/or interchangeability
established donor and acceptor function. Variations in acceptor COM domain did
not result in novel product formation in the presence of its partner donor, whereas
plipastatin formation was completely abrogated by altering donor modules. Five novel
lipopeptides (cyclic pentapeptide, linear hexapeptide, nonapeptide, heptapeptide, and
cyclic octapeptide) were identified and verified by high-resolution LC-ESI-MS/MS. In
addition, we demonstrated the potential to generate novel strains with the antimicrobial
activity by selecting compatible COM domains, and the novel lipopeptides exhibited
antimicrobial activity against five of the fungal species at a contention of 31.25–125
µg/ml.
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INTRODUCTION
Bacillus subtilis is a Gram-positive bacterium that produces broad spectrum amphiphilic
lipopeptides with excellent biosurfactant properties and antifungal, antibacterial and antiviral
activities (Marahiel et al., 1997; Schwarzer et al., 2003; Batool et al., 2011). Iturins (Hiradate et al.,
2002; Yu et al., 2002; Jin et al., 2014), fengycins (Vanittanakom et al., 1986; Guo et al., 2014)
and surfactins (Bonmatin et al., 2003; Liu et al., 2015) are the three most well-known families of
lipopeptides, which produced by Bacilli. And all of them are synthesized by nonribosomal peptide
synthetases via a thioesterase chain release mechanism (Tosato et al., 1997; Finking and Marahiel,
2004; Calcott and Ackerley, 2014). These lipopeptides contain a variable cyclic amino acid portion
attached to a variable β-amino or β-hydroxy fatty acid (de Faria et al., 2011). The fengycin is
actually identical compounds to plipastatin that display slightly structural variations at different
salty conditions (Honma et al., 2012). Therefore, the term plipastatin is used throughout this study.
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Plipastatin is composed of 10 α-amino acids linked to one unique
β-hydroxy fatty acid chain, and two variants (plipastatin A and
B) with Val or Ala at position 6 have been reported (Vater
et al., 2002; Sun et al., 2006). Plipastatin synthetase contains
five distinct NRPSs subunits which assemble to form a co-linear
chain in the order of ppsA-ppsB-ppsC-ppsD-ppsE (Figure 1A)
that incorporates two (ppsA, B and C), three (ppsD), and one
(ppsE) amino acid residues (Figure 1B) into the growing peptide,
respectively (Marahiel et al., 1997).
Based on the molecular mechanisms employed by NRPSs,
NRPS assembly lines have an enormous potential for
biocombinatorial synthesis. Biosynthesis of a defined, full-length
product relies on the selectivity of individual modules and their
coordinated interplay with donor and acceptor communication-
mediating (COM) domains (Chiocchini et al., 2006). In most
bacterial NRPS systems, a donor COM domain (COMDX ) situated
at the C terminus of an aminoacyl- or peptidyl-donating NRPS
(X) and an acceptor COM domain (COMA) located at the N
terminus of the accepting partner enzyme (Y) form a matching
(compatible) set that forms productive interactions between
FIGURE 1 | The plipastatin biosynthetic system. (A) The enzymatic assembly line of plipastatin consists of five NRPSs, encoded by the polycistronic genes
ppsABCDE. (B) The synthetases ppsA, ppsB, ppsC, ppsD, and ppsE are composed of two, two, two, three, and one module(s), respectively. (C) Variations of COM
domains: (i) point mutation of donor ppsB; (ii) deletion of donor ppsC; (iii) four permutations: the acceptor of ppsC replaced with ppsB; the donor of ppsD replaced
with ppsC; the acceptor of ppsB replaced with ppsC; and the donor of ppsC replaced with ppsD; (iv) the deletion of donor ppsC and the acceptor of ppsC replaced
with ppsB. (D) The novel peptides caused by the COM changes corresponding to the lipopeptides in Table 1.
adjacent modules (i.e., ppsA ppsB1 and ppsB2 ppsC1) (Hahn
and Stachelhaus, 2006). Biochemical investigations on the
selectivity of NRPSs have helped define sets of compatible
inter-module linkers. In principle and in practice, enzymes
of a NRPS complex can form other biosynthetic templates,
making possible the synthesis of a vast array of novel peptide
products via a process that is tantamount to combinatorial
synthesis (Sieber and Marahiel, 2005; Fischbach and Walsh,
2006). The COM domain swapping experiments verified the
decisive role of COM domains for the control of protein-protein
interactions between surfactin NRPS (Chiocchini et al., 2006).
The research had demonstrated that point mutation of one
of these key residues within the COM domain of TycC1 was
sufficient to shift its selectivity from the cognate donor COM of
TycB3 toward the noncognate donor COM domain of TycB1 in
tyrocidine NRPSs (Hahn and Stachelhaus, 2006). The fragments
of COM domains were sequenced in previous study (Hahn and
Stachelhaus, 2006), but the interaction between enzymes of a
nonribosomal peptide has hardly been studied, which relies
on the interplay of COM domains. Therefore, we attempted to
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investigate the biocombinatorial synthesis of novel lipopeptides
by COM domain-mediated reprogramming of the plipastatin
NRPS complex.
The goal of this study was to investigate the influence on
protein–protein communication based on the converting donor
and acceptor of COM domains sequences, which maintain
or prevent the selective interaction between partner NRPSs,
furthermore the influence on the novel lipopeptides formation.
In this work we began with the B. subtilis PB2-L strain from
our previous work, which produces plipastatin (Figure S5)
following integration of a gene expression frame composed of
a constitutive promoter P43, functional gene sfp, and regulatory
gene degQ into the chromosomal amyE locus of PB2. We studied
the importance of COM domains in mediating the specific
channeling of reaction intermediates between partner enzymes.
First, the effect of site directed mutagenesis of module ppsB
on protein-protein communication with the partner elongation
module ppsC was explored. Subsequently, the importance and
generality of COM domains was further substantiated by COM
domain deletion and permutation experiments. This research
may provide the theoretical basement for the biocombinatorial
synthesis of NRPS complex and the exploitation of novel
lipopeptides.
MATERIALS AND METHODS
Strains, Media, and General Methods
Bacterial strains and plasmids used in this work are listed in
Table S1. Escherichia coli and Bacillus subtilis were grown in LB
medium supplemented with 100 mg/ml ampicillin, 20 mg/ml
kanamycin, or 5 mg/ml erythromycin (final concentrations)
where applicable. All enzymes were commercial preparations and
were used as specified by the suppliers (Vazyme Biotech Co.,Ltd,
Nanjing, China and Takara Shuzo Co., Ltd, Dalian, China).
E. coli transformation was performed as described previously
(Sambrook et al., 1989). The plipastatin biosynthetic complex was
reprogrammed using a homologous recombination approach
(Figure S1) with upstream (A1) and downstream (A2) primers to
construct plasmid pks2A1A2. Similarly, upstream B1 (targeting
the tgf gene fragments) and downstream B2 were used to
generate plasmid pks2B1B2. The constructs was verified by PCR
analysis and used for deletion and substitutions, respectively.
After transformation of the plasmids into the host, plasmids were
inserted into the chromosome by homologous recombination
between the target gene and homologous sequences, or between
the homologous sequences alone via the well-established two-
step exchange method (Chiocchini et al., 2006). Integration
into the chromosome by a single crossover event was selected
during growth at the nonpermissive temperature (37◦C) while
maintaining selective pressure. Subsequent growth of the
cointegrates at the permissive temperature (30◦C) leads to
a second recombination event, resulting in their resolution
(Arnaud et al., 2004). The novel B.subtilis strains were verified
by PCR analysis and the sequences were sequenced by
Genscript biotechnology co., LTD (Nanjing, China) (data not
shown).
Cloning
Bacillus subtilis DNA was isolated from enrichment cultures
using a bacterial genomic DNA extraction kit (Omega, USA)
according to the manufacturer’s instructions. Each 50 µl reaction
contained 35 µl of ddH2O, 5 µl of 2 × PCR buffer, 4 µl of
dNTP, 2 µl of F-primer, 2 µl of R-primer, 1 µl of Phanta Super-
Fidelity DNA Polymerase and 1 µl of template DNA. The PCR
program consisted of an initial denaturation at 94◦C for 3 min,
followed by 30 amplification cycles of 94◦C for 30 s, 60◦C for 30 s,
and 72◦C for 30 s, then 72◦C for 10 min. Primers (Supplemental
Data) were purchased from Sangon Biotech (Shanghai, China).
Standard procedures were applied for all DNA manipulations
(Sambrook et al., 1989).
A 1382 bp product containing the COMppsB fragment
was amplified using oligonucleotides ppsB-F and ppsB-R. The
resulting product was digested with SphI and SalI and cloned into
the E. coli expression vector PMD-19 that was digested with the
same enzymes to give pCC42. After digestion with SphI and SalI,
the fragment was ligated into pKS2 to give pKSA1. Based on the
21 bp overlapping region in M-F and M-R, pKSA1 was used as
template for the subsequent PCR with oligonucleotides M-F and
M-R to generate point mutations.
Two 600 bp ppsC fragments were amplified using
oligonucleotides K-up-F and K-up-R, and K-down-F and
K-down-R, respectively. After cloning into the E. coli expression
vector PMD-19 and digestion with ClaI, SalI, SalI, and KpnI,
the fragments were ligated into pKS2 to give pKSK1, which
was used as template for PCR with oligonucleotides P1-F and
P1-R to gain the pKSP1 for use in the initial substitution step.
Subsequently, 650 bp upstream and downstream gene fragments
were amplified by PCR and the target COMDppsC (the donor
COM of ppsC) fragment was combined with the downstream
fragment by fusion PCR using the oligonucleotides P2-down1-F
and P2-down2-F. The resultant product was digested with SalI
and KpnI and ligated into pKS2 that was also digested with
these enzymes, and oligonucleotides P2-up-F and P2-down-
R were used to generate pKSP2. Next, PCR was performed
using oligonucleotides P3-F and P3-R and pKSK1 as template
to generate pKSP3 for permutation in the third step of the
procedure. To this end, 650 bp upstream and downstream
fragments were amplified using oligonucleotides P4-up-F,
P4-up-R, P4-down3-F, and P4-down-R, while a 72 bp fragment
of COMDppsD was amplified using oligonucleotides P4-down1-F
and P4-down2-F. After purification, DNA fragments were
combined and used as template for PCR amplification with
oligonucleotides P4-up-F and P4-down-R, and subsequent
cloning into pKS2 yielded the final disruption vector pKSP4
(Table S1). The maps of plasmids used to construct the deletion
mutant, point mutation and substitution were shown in Figures
S3, S4, respectively.
B. subtilis Strain Construction
Transformations were carried out as described previously
(Anagnostopoulos and Spizizen, 1961), and genotypes
were verified by PCR. The pKSA1, pKSK1, and pKSP1
plasmids were transformed into B. subtilis PB2-L, B. subtilis
PB2-LP1 was transformed with pKSP2, and the resulting
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TABLE 1 | Lipopeptides, retention times, m/z values of protonated forms and peptide sequences.
Approach of COM
changes
Homologues
of peptides
RT (min) Molecular formula Mass (m/z) Peptide sequence
Point mutation of donor
ppsB (T7D)
A1 13.94 n = 12; C45H74N6O11 875.5498 β-OHFA-ABE
A2 14.15 n = 13; C46H76N6O11 889.5688 Cyclo pentapeptide
A3 14.15 n = 14; C47H78N6O11 903.5841 CH3(CH2)n1CHOHCH2CO-Glu-Orn-
A4 14.15 n = 15; C48H80N6O11 917.6087 Tyr-Thr –Ile; n1 = 12-15
O 
Deletion of donor ppsC B1 13.07 n = 10; C47H77N7O15 980.5580
B2 13.15 n = 11; C48H79N7O15 994.5712
B3 13.20 n = 12; C49H81N7O15 1008.5873 β-OHFA-ABC
B4 13.68 n = 13; C50H83N7O15 1022.6026 Linear hexapeptide
B5 14.15 n = 14; C51H85N7O15 1036.6179 CH3(CH2)n2CHOHCH2CO-Glu-Orn-Tyr-Thr -Glu-
Val; n2 = 10–16
B6 14.15 n = 15; C52H87N7O15 1050.6338
B7 14.15 n = 16; C53H89N7O15 1064.6493
the donor of ppsD
replaced with ppsC
C1 15.63 n = 11; C67H103N11O20 1382.7556 β-OHFA-ABCD
C2 15.63 n = 12; C68H105N11O20 1396.7715 Linear nonapeptide
C3 15.98 n = 13; C69H107N11O20 1410.7876 CH3(CH2)n3CHOHCH2CO-
Glu-Orn-Tyr-Thr-Glu-Val-Pro-Gln-Tyr; n3 = 11–13
the acceptor of ppsB
replaced with ppsC
D1 12.15 n = 10; C66H101N11O20 1368.7387 β-OHFA-ABCD
D2 12.33 n = 11; C67H103N11O20 1382.7517 Linear nonapeptide
D3 13.15 n = 12; C68H105N11O20 1396.7667 CH3(CH2)n4CHOHCH2CO-
D4 13.68 n = 13; C69H107N11O20 1410.7817 Glu-Orn-Tyr-Thr -Glu-Val -Pro-Gln-Tyr;n4 = 11–14
the donor of ppsC
replaced with ppsD
E1 13.52 n = 12; C53H88N8O16 1093.6393
E2 13.68 n = 13; C54H90N8O16 1107.6598 β-OHFA-ABCE
E3 14.15 n = 14; C55H92N8O16 1121.6753 Linear heptapeptide
E4 14.69 n = 15; C56H94N8O16 1135.6871 CH3(CH2)n5CHOHCH2CO-Glu-Orn-
E5 14.69 n = 16; C57H96N8O16 1149.7043 Tyr-Thr-Glu-Ala –Ile; n5 = 12–16
Deletion of donor ppsC
and the acceptor of
ppsC replaced with
ppsB
F1 17.05 n = 12; C64H98N10O16 1263.7235 β-OHFA-ABDE
F2 17.12 n = 13; C65H100N10O16 1277.7412 Cyclo octapeptide
F3 17.68 n = 14; C66H102N10O16 1291.7504 CH3(CH2)n6CHOHCH2CO-Glu-Orn
F4 18.06 n = 15; C67H104N10O16 1305.7682 -Tyr-Thr-Pro-Gln-Tyr -Ile; n6 = 12-15
O                  
β-OHFA-ABE, The lipopeptides produced by NRPS complex assembly line ppsA, ppsB, and ppsE; β-OHFA-ABC, The lipopeptides produced by NRPS complex assembly line ppsA,
ppsB, and ppsC; β-OHFA-ABCD, The lipopeptides produced by NRPS complex assembly line ppsA, ppsB, ppsC, and ppsD; β-OHFA-ABCE, The lipopeptides produced by NRPS
complex assembly line ppsA, ppsB, ppsC, and ppsE; β-OHFA-ABDE, The lipopeptides produced by NRPS complex assembly line ppsA, ppsB, ppsD, and ppsE.
strain was transformed with pKSP3 and pKSP4, generating
B. subtilis mutants PB2-LA1 (COMDppsBT::D), PB2-LK1
(1COMDppsC), PB2-LP1 (COM
A
ppsC:: COM
A
ppsB), PB2-LP2
(COMAppsC:: COM
A
ppsB and COM
D
ppsD:: COM
D
ppsC), PB2-LP3
(COMAppsC:: COM
A
ppsB, COM
D
ppsD:: COM
D
ppsC and COM
A
ppsB::
COMAppsC), and PB2-LP4 (COM
A
ppsC:: COM
A
ppsB, COM
D
ppsD::
COMDppsC, COM
A
ppsB:: COM
A
ppsC and COM
D
ppsC:: COM
D
ppsD).
The pKSK1 and pKSP1 plasmids were transformed into
B. subtilis PB2-L in two steps to give B. subtilis mutants
PB2-LK1 (1COMDppsC) and PB2-LKP1 (1COM
D
ppsC, COM
A
ppsC::
COMAppsB) (Table S1).
Production of Antimicrobial Extracts
Modified strains were cultivated in Landy medium
(20 g/L glucose, 1 g/L yeast extract, 5 g/L L-glutamic acid,
1 g/L KH2PO4, 0.16mg/L CuSO4, 0.5 g/L MgSO4·7H2O,
0.15mg/L FeSO4, 0.5 g/L KCl, 5 mg/L MnSO4·H2O, pH 7.0)
at 33◦C in a rotary shaker at 180 rpm for 3 days to produce
antimicrobial substances (Landy et al., 1947; Deng et al., 2011b).
Antimicrobial extracts were obtained using an organic solvent
(methanol) extraction method.
Product Formation Assays
The crude methanol extract was fractioned by the high resolution
LC-ESI-MS and LC-ESI-MS/MS analysis, which was performed
Frontiers in Microbiology | www.frontiersin.org 4 November 2016 | Volume 7 | Article 1801
Liu et al. Reprogramming of the Plipastatin NRPS Complex
with a Thermo Finnigan Surveyor-LCQ DECA XP Plus (Thermo
Electron Corporation, San Jose, CA, USA). The flow rate was
maintained at 0.2 mL/min with a gradient of 22 min (0–95 %,
vol/vol acetonitrile for 18 min and 95–5%, vol/vol acetonitrile for
4 min). The electrospray needle was operated at a spray voltage
of 5 kV, a capillary voltage of 32 V and a capillary temperature
of 300◦C. For the HCD experiment, helium was used as the
collision gas and the collision energy was set at 35%. Elution was
monitored by UV detection at 214 nm (Mootz et al., 2000; Deng
et al., 2011b).
Determination of Antimicrobial Activity
The linear products were synthetized by KareBay BioChem, Inc.
Antimicrobial activity was evaluated by determining MIC values
using the standard broth microdilution method (Nedorostova
et al., 2009) with some modifications. Tested microorganisms
were incubated at 37 or 30◦C to approximately 106–107 CFU/ml
in lysogeny broth (LB) medium. Serial dilutions of antimicrobial
compounds were prepared to obtain final concentrations of
1000, 500, 250, 125, 62.5, 31.25, 15.63, and 7.81 µg/ml in
LB or PDA medium. The ability of cyclic products strains to
inhibit the growth of various indicator organismswas determined
qualitatively by agar-well diffusion method (Deng et al., 2011a).
Plates were incubated for up to 24 (bacteria) and 48 h (fungi)
before the antimicrobial activities were determined (Oh et al.,
2011). Samples incubated without antimicrobials were used as
controls.
RESULTS
Influence of a ppsB Donor Point Mutation
on Plipastatin Synthesis
To demonstrate the biocombinatorial potential of COM
domains, we investigated crosstalk between ppsB and ppsC
modules through point mutations. Seven positions in COMDppsB
(Figure 1C) were mutated as follows: W1K, S2T, A3L, T7D, E9K,
D10S, and G12S. We evaluated the impact of COMDppsB point
mutants on lipopeptide biosynthesis.
Based on the high-resolution LC-ESI–MS spectra, all the
point mutants did not produce novel lipopeptides (data not
shown) except for the T7D mutation. In high-resolution ESI–MS
spectra, a series of charge 1 (z = 1) molecular ions with
m/z values at 875.5488, 889.5644, 903.5801, and 917.5963
(Figure 2A) led us to predict the formation of a β-OH fatty
acid (β-OHFA)-ABE product. And the predicted formula was
C46H76N6O11 (ppm = 4.831) at m/z 889.5644. Using the
HCD–MS/MS spectrum of the precursor ion [M + H]+ at
m/z of 889.5644 (Figure 2B), -b and -y productions (Pathak
et al., 2013) were assigned (Figure 2C), which enabled us to
infer the sequence cyclo-[β-OHFA-Glu-Orn- Tyr-Thr -Ile]. The
formula (C46H76N6O11) was consistent with the results of
mass spectrometry (Table 1). The molecular mass ions at m/z
875.5488, 903.5801, and 917.5963 were found to be derived from
a β-OHFA chain variant atm/z 889.5644 sharing the same peptide
sequence (Figure 1D), based on the fragment ion profile obtained
by high-resolution HCD–MS/MS. These lipopeptide precursor
ions with a 14 Da (Yang et al., 2015) mass difference from
m/z 889.5644 ion were assigned as new pentapeptide variants
differing only in β-OHFA chain length.
The T7D mutation resulted in a loss in the ability of the
COMD domain to form a productive complex with its native
partner COMAppsB (the acceptor COM of ppsB). However, at
the same time, ppsB point mutant gained the ability to interact
with the ppsE. Meanwhile, a novel NRPS complex assembly
line ppsA, ppsB and ppsE was formed. This indicated that the
mutation of threonine in the donor COM domain of ppsB to
aspartic acid was sufficient to transfer selectivity from the cognate
acceptor COM toward the noncognate accepter COM of ppsD,
and highlights the importance of the threonine residue at this
position in protein-protein communication.
Influence of ppsC Donor Deletion Mutant
on Plipastatin Synthesis
The deletion of ppsC donor on the ability to interact with
the partner elongation module ppsD was investigated in vivo
(Figure 1C). As shown in Table 1, the high-resolution ESI–MS
revealed a series of charge 1 (z = 1) ions with m/z at
980.5560, 994.5712, 1008.5873, 1022.6026, 1036.6179, 1050.6338,
and 1064.6493 (Figure 3A) that eluted with a retention time
between 13.07 and 14.15 min. And the predicted formula
was C49H81N7O15 (ppm = 0.673) at m/z 1008.5873. And the
high-resolution HCD-MS/MS spectrum of the precursor ion
(Figure 3B) was analyzed, and -b and -y ions were consistent
with a linear [β-OHFA-Glu-Orn- Tyr-Thr-Glu-Val] peptide
(Figure 3C), which lacked four amino acid residues (Pro, Gln,
Tyr, and Ile) that are present in plipastatin. The formula of
linear peptide was in accord with the MS spectra analysis.
Furthermore, other molecular ions were clearly derived from
this peptide moiety, and the 14 Da differences again indicated
varying chain length of the β-OHFA (Figure 1D). The COMDppsC
deletion largely resulted in a loss in the ability of the COMD
domain to form a productive complex with its native partner
COMAppsC. The deletion mutant was completely inactive in a
product formation assay with ppsD, resulting in formation of the
novel NRPS complex assembly line ppsA, ppsB, and ppsC.
Influence of Interchangeabilities in COM
Domain on Plipastatin Synthesis
Indeed, deletion of the donor module ppsC prevents plipastatin
biosynthesis. However, the inability of mutant systems to
synthesize plipastatin and the formation of novel products is due
to either the loss of protein–protein interaction between donor
and acceptor NRPS partners, or inactivity of donor modules
causing by the deletion of the most C-terminal amino acid
residues.
To challenge these potential explanations, crosstalk
experiments were performed, which confirmed that members
of the compatible pairs between ppsB and ppsC, ppsC and
ppsD, as well as ppsD and ppsE were interchangeable in vivo.
First, acceptor ppsC was initially swapped with ppsB, and donor
ppsD was subsequently substituted with donor ppsC. Next,
acceptor ppsB was mutated to acceptor ppsC, and donor ppsC
was replaced by donor ppsD. Plipastatin was observed in the
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FIGURE 2 | (A) The high-resolution ESI–MS of cyclic pentapeptide ions with retention time (RT) 14.15 min and (B) HCD–MS/MS of the precursor ion [M + H]+ at m/z
889.5688, (C) which was confirmed as a novel pentapeptide consisting of Glu-Orn-Tyr-Thr-Ile and a C13 β-OH fatty acid chain.
methanolic extract when acceptor ppsC was replaced by acceptor
ppsB (data not shown), and the anticipated novel product was not
formed. However, when COMDppsD was replaced by COM
D
ppsC,
the high-resolution ESI–MS gave the charge 1 molecular mass
ions of m/z 1382.7556, 1396.7715, and 1410.7876 (Figure 4A),
which were assigned as hydrogen adducts of corresponding
protonated novel nonapeptide ions. The charge 2 (z = 2) of the
mass ions was 691.8796, 698.8879, and 705.8953, which verified
the predicted formula was C68H105N11O20(ppm = 4.333).
In order to confirm the assignments, the m/z 1396.7715
ion was subjected to the high-resolution HCD-MS/MS
(Figure 4B), and the -y ion series at m/z 736.3506 (−H2O,
718.3523)→508.2406→407.1911→ 310.1407→ 181.0986 was
consistent with Glu-Val-Pro-Gln-Tyr from the N-terminus,
while the -b ion series 762.4486→661.4158→ 498.3586→
384.2732 suggested that the precursor ion possessed a Glu-Orn-
Tyr-Thr at the C-terminus and a C12 β-OH fatty acid that lacked
the Ile residue present in plipastatin, and the fragmentation
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FIGURE 3 | (A) The high-resolution ESI–MS of linear hexapeptide ions with RT in the range 13.07–14.15 min and (B) HCD–MS/MS of the precursor ion [M + H]+ at
m/z 1008.5873, (C) which was confirmed as a novel hexapeptide consisting of Glu-Orn-Tyr-Thr-Glu-Val and a C12 β-OH fatty acid chain.
pattern for the entire m/z 1396.7715 is consistent with MS/MS
analysis (Figure 4C). Again, other molecular mass ions differing
by 14 Da (−CH2−) were clearly derived from the same peptide
sequence but with C11 and C13 β-OH fatty acids, respectively
(Table 1, Figure 1D). This indicated that the donor of ppsD
loss the ability of forming a productive complex with its native
partner, and resulting the formation of the NRPS complex
assembly line ppsA, ppsB, ppsC and ppsD.
Subsequent mutation of acceptor ppsB to acceptor ppsC
was predicted to result in a product with one further
modification. The charge 1 (z = 1) molecular mass ions at
m/z 1368.7387, 1382.7517, 1396.7667, and 1410.7817 and the
charge 2 (z = 2) of the mass ions at m/z 684.8743, 691.8776,
698.8860, and 705.8932 were observed in the high-resolution
ESI–MS spectrum (Figure S6A), which verified the predicted
formula at m/z 1396.7667 was C68H105N11O20(ppm = 4.181).
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FIGURE 4 | (A) The high-resolution ESI–MS of linear nonapeptide ions with RT 13.35 min and (B) HCD–MS/MS of the precursor ion [M + H]+ at m/z 1396.7715, (C)
which was confirmed as a novel nonapeptide consisting of Glu-Orn-Tyr-Thr-Glu-Val-Pro- Gln-Tyr and a C12 β-OH fatty acid chain.
The high-resolution HCD-MS/MS fragmentation of the m/z
1396.7667 ion (Figure S6B) yielded a series of -b fragment ions at
m/z 891.5045762.4468→ 661.4145→498.3531→384.2725 and -y
fragment ions at m/z 736.3506 (−H2O, 718.3517)→508.2404→
407.1911 →310.1393→ 181.0977 that were consistent with
hydrogen adducts of a C12 β-OH FA and an nonapeptide
with the sequence Glu-Orn-Tyr-Thr-Glu-Val- Pro-Gln- Tyr that
is the same as that obtained with the modification described
above, and is also lacking the Ile residue comparing the original
product plipastatin. The result showed that the NRPS complex
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generated the assembly line ppsA, ppsB, ppsC, and ppsD. Finally,
COMDppsB was replaced with COM
D
ppsD, this caused the disability
of COMDppsB operon and generation of COM
D
ppsB mutated to
COMDppsD as expected. The high-resolution ESI–MS spectrum
again included hydrogen adduct charge 1 (z = 1) mass ions
differing by multiples of 14 Da that eluted between 13.52
and 14.69 min (Figure 5A). The formula of the [M + H]+
ion at m/z 1107.6598 was C54H90N8O16(ppm = 3.553) with
the mass spectrum analysis. The high-resolution HCD-MS/MS
fragmentation ofm/z 1107.6598 ion eluting at 13.68 min resulted
in -b and -y ion assignments (Figure 5C) consistent with a linear
heptapeptide with a linear C13 β-OH FA and the sequence
Glu-Orn-Tyr-Thr-Glu-Ala-Ile (Figure 5B). This sequence was
produced by the NRPS complex assembly line ppsA, ppsB, ppsC,
FIGURE 5 | (A) The high-resolution ESI–MS of linear heptapeptide ions eluted with RT in the range 13.52–14.69 min and (B) HCD–MS/MS of the precursor ion [M +
H]+ at m/z 1107.6598, (C) which was confirmed as a novel heptapeptide consisting of Glu-Orn-Tyr-Thr-Glu-Ala-Ile and a C13 β-OH fatty acid chain.
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and ppsE, and lacks three amino acid residues (Pro, Gln and
Tyr) that are present in plipastatin. Other linear heptapeptides
identified in this study are summarized in Table 1, Figure 1D.
Experiments unequivocally confirmed that the acceptor modules
did not contribute to the formation of novel products, however,
all tested donor modules were equally able to change the native
system synthesizing plipastatin.
Influence of Combined Deletion and
Substitution of COM Domains on
Plipastatin Synthesis
The second experiment demonstrated that the ppsC module
could not couple with the next ppsDmodule following deletion of
the ppsC donor. However, when the partner donor was present,
altering the acceptor module had no effect on the formation of
novel lipopeptides in the permutation experiment. We therefore
decided to investigate whether the acceptor module retains the
ability to interact when its partner donor module is deleted. The
donor of ppsC was first deleted, and the acceptor of ppsC was
then substituted with the acceptor of ppsB (Figure 1C). The high-
resolution ESI–MS analysis of the resulting product gave a charge
1 (z = 1) molecular mass ion series ofm/z 1263.7235, 1277.7412,
1291.7504, and 1305.7682 (Figure 6A) that corresponded with
hydrogen adducts of ions derived from a novel cyclic octapeptide.
The predicted formula was C65H100N10O16 (ppm = 1.132) at
m/z 1277.7412. The high-resolution HCD-MS/MS fragmentation
of the m/z 1277.7412 ion (Figure 6B) yielded a -y ion series
at m/z 102.0553→766.3765→881.4631 from the N-terminus,
and a -b ion series at m/z 226.1178→389.4315→502.2661
→398.2906→512.3785 from the C-terminus, consistent with
a cyclic Glu-Orn-Tyr- Thr-Pro-Gln-Tyr-Ile peptide and a C13
β-OH fatty acid lacking Glu and Ala/Val amino acid residues
that are present in plipastatin and the fragmentation pattern
is illustrated in Figure 6C. Again, other molecular mass ions
(Table 1, Figure 1D) differing by 14 Da (−CH2−) were derived
from the same peptide but with C11, C12, and C14 β-OH fatty
acids. This indicated that a novel NRPS complex assembly line
ppsA, ppsB, ppsD and ppsE directed the production of cyclic
octapeptide.
Deletion of donor of ppsC largely abrogated the ability of the
COMD domain to form a productive complex with its native
partner COMAppsC, but formation of plipastatin was not affected
when the acceptor of ppsC was substituted with the acceptor
of ppsB. However, the including of both modifications mutant
resulted in the ability of ppsB to interact with the ppsC acceptor
(COMAppsC). Therefore, the acceptor module retained selectivity
when its partner donor module was deleted.
Antimicrobial Activity
The antimicrobial activity of the linear lipopeptide products was
tested against one Gram-positive bacteria, one Gram-negative
bacteria and five fungi using a standard dilution approach.
The lipopeptides exhibited antimicrobial activity against five
of the fungal species at a contention of 31.25–125 µg/ml
(Table 2). Interestingly, the novel lipopeptides inhibited both
tested bacteria. Penicillium notatum exhibited the least resistance
against linear heptapeptide and hexapeptide compared with all
fungi, showing a MIC of 31.25 µg/ml, which was the value
of the linear heptapeptide against Aspergillus ochraceus. The
MIC values of all linear lipopeptides against Escherichia coli and
Staphylococcus aureus were much higher than against the fungi,
and the MIC values were, respectively, 250 and 500 µg/ml. The
cyclic lipopeptides exhibited the inhibitory activity as shown in
Figure S7.
DISCUSSION
Based on the characterization of NRPS systems, each of
the large modular enzymes is deemed responsible for the
incorporation of a monomeric precursor into a specific amino
acid (Walsh, 2002; Schwarzer et al., 2003). In multienzymatic
NRPS complexes, synthesis by most known NRP assembly
lines requires appropriate communication between partner
enzymes including A-PCP minimal modules (Schneider et al.,
1998), C-A-PCP elongation modules (Mootz et al., 2002),
A domains (Eppelmann et al., 2002), and translocation of
the terminal, product-releasing Te domains (de Ferra et al.,
1997). A recent study has examined the interaction between
NRPS modules by introducing the photocrosslinking unnatural
amino acidBpF (Chin et al., 2002) into aminimal, dimodular
NRPS system. Further, the crosslinks were Photocrosslinked
and mapped of by MS (Dehling et al., 2016). In addition,
protein-protein communication is controlled by the interplay
between linker (COM) domains that comprise only 20–30 or
15–25 amino acid residues, and that are located at the C and
N termini between NRPS enzyme modular domains (Hahn
and Stachelhaus, 2004). The selectivity provided by different
sets of compatible COMD and COMA domains results in
NRPS complexes that utilize defined biosynthetic templates and
synthesize specific peptide products (Hahn and Stachelhaus,
2004, 2006).
In the present study, we investigated the selectivity of COM
domains by direct reprogramming of the plipastatin biosynthetic
complex, and achieved a biocombinatorial synthesis of new
lipopeptides possessing significant antimicrobial activity. Novel
lipopeptides sequences were identified by the structure of
plipastatin (Deleu et al., 2008) coupled with HCD-MS/MS
fragmentation (Pathak et al., 2013). In the first part of the
study, the amino acid substitutions can be classified into four
groups: (i) conservative exchanges between hydrophobic amino
acids (A3L) and polar uncharged residues (S2T and G12S), (ii)
substitution of a hydrophobic with a polar residue (W1K), (iii)
exchange of a polar uncharged residue for a negatively charged
residue (T7D), and (iv) substitution of a polar negatively charged
residue with a polar positively charged (E9K) or uncharged
(D10S) amino acid. The key residues that mediate the interaction
between donor ppsB and acceptor ppsC COM domains were
mutated, and the resultant NRPS system was able to form a
novel assembly line (ppsA/ppsB/ppsE) that could synthesize
lipopentapeptides. Indeed, a Thr-to-Asp mutation resulted
in a series of homologous shortened pentapeptide products
(Table 1). The previous research demonstrated that the selective
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FIGURE 6 | (A) The high-resolution ESI–MS of cyclic octapeptide ions with RT in the range 17.01–18.41 min and (B) HCD–MS/MS of the precursor ion [M + H]+ at
m/z 1277.7412, (C) which was confirmed as a novel cyclic octapeptide consisting of Glu-Orn-Tyr-Thr-Pro-Gln-Tyr-Ile and a C13 β-OH fatty acid chain.
communication is predominantly established by polar and/or
electrostatic interactions in tyrocidine NRPS complex (Hahn and
Stachelhaus, 2006). However, the substitution of a hydrophobic
with a polar residue (W1K) did not change the selectivity.
Therefore, the electrostatic interactions might play a key role in
the selective communication. This approach can therefore be
used to identify key residues that are important for maintaining
(or preventing) the interaction between COMD and COMA
in NRPSs. Deletion of the ppsC donor prevented selectivity
of the acceptor of ppsC, and resulted in a novel assembly line
(ppsA/ppsB/ppsC) that synthesized a lipohexapeptide. It was
also demonstrated that the COMA domain alone is insufficient
for interacting with its upstream partner enzyme in the enzyme
complex with specificity (Cheng et al., 2016). We next questioned
whether both the donor and acceptor COM domains influence
the selectivity by switching the acceptors of ppsC and ppsB. The
differences between respective COM domain pairs were minimal
(Figure S2) (Linne et al., 2003), and the mutation of acceptor
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TABLE 2 | Minimum inhibitory concentration (MIC) of lipopeptides against
fungal species (µg/mL).
Fungal Linear Linear Linear
species hexapeptide nonapeptide heptapeptide
Rhizopus stolonifer 62.5 62.5 62.5
Fusarium oxysporum 62.5 62.5 62.5
Aspergillus ochraceus 62.5 62.5 31.25
Penicillium notatum 31.25 62.5 31.25
Aspergillus flavus 62.5 125 125
Escherichia coli 250 500 250
Staphylococcus aureus 250 500 500
COM domains impairs rather than halts product formation. In
contrast, formation of plipastatin was not only impaired but
completely abrogated when donor modules of COM domains
were changed, and resulted in formation of new assembly
lines (ppsA/ppsB/ppsC/ppsD and ppsA/ppsB/ppsC/ppsE)
that synthesized novel lipononapeptide and lipoheptapeptide
products. These results further demonstrated that donor COM
domains influence interactions in the biosynthetic assembly line.
Deletion of the ppsC donor ceased the interaction with its partner
acceptor module, but when the partner acceptor module was
mutated to the acceptor of ppsB, which facilitated the synthesis
of a novel assembly line (ppsA/ppsB/ppsD/ppsE). Therefore, the
acceptor COM domains retain selectivity when their partner
donor is deleted. It was previously shown that when all donor and
acceptor were replaced with the same (compatible) COMD and
COMA domains in the surfactin biosynthetic complex, different
assembly lines (SrfA-A/SrfA-B/SrfA-C and SrfA-A/SrfA-C)
were formed that led to the synthesis of lipoheptapeptide
and the lipotetrapeptide products (Chiocchini et al., 2006). A
universal communication system for the plipastatin biosynthetic
complex is therefore likely to result in additional novel
lipopeptides.
Nonribosomal peptides synthetases (NRPSs) synthesis
structurally diverse peptide-based natural products (Marahiel
and Essen, 2009). Manipulation of their modular organization
provides enormous potential for generating novel bioactive
compounds (Miao et al., 2006; Butz et al., 2008; Doekel
et al., 2008). Matching pairs of COM domains form protein–
protein interactions (Linne et al., 2003; Hahn and Stachelhaus,
2006), and the present study demonstrated the decisive role
of COM domain pairs in NRP biosynthetic complexes. The
need for new antibiotics to fight the emergence of resistant
pathogenic microorganisms is growing (Marr et al., 2006),
and the novel lipopeptides proved to have good antimicrobial
activity.
CONCLUSIONS
Our results and experimental approaches pave the way for (1)
identifying key residues in COM domains (2) characterizing the
interactions between donor and acceptor COM domains, and (3)
the preparation of novel lipopeptides possessing antimicrobial
activity. Donor or acceptor modules could therefore influence
the selectivity of NRPS systems. We demonstrated that (1) a
single point mutation of a COM domain can alter the selectivity
of the biosynthetic assembly line, (2) donor COM domains
influence interactions in the biosynthetic assembly line, (3)
mutation of acceptor COM domains impairs rather than halts
product formation, (4) acceptor COM domains retain selectivity
when their partner donor is deleted, and (5) the lipopeptides
possess strong antifungal and some antibacterial activity. Our
experimental approaches provide the theoretical basis for the
production of the novel lipopeptides, which has potential for use
in food preservation.
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